Medical Case Reports

While there are certain genetic and environmental factors that may increase an individual's risk of developing anaphylaxis in general, there is currently no specific biomarker or genetic test that can reliably predict an individual's risk of anaphylaxis to vaccines. The decision to administer a vaccine to an individual with a history of anaphylaxis is recommended to be made on a case-by-case basis.  Recent paper describes a case where PEG skin testing was useful in predicting an allergic reaction to BNT162b2 vaccine.  We note that there have been some reports of successful PEG skin testing in certain non-COVID-vaccine-related cases in the past, but the reliability of this method has not been established through systematic research studies and the skin test could be life-threatening in some cases.  There is a lack of standardization in the PEG skin test procedure, including the concentration and method of application of the PEG test solution, which makes it difficult to in...

79-year old female, resident of a retirement home in Maple Ridge of British Columbia    with history of  chronic obstructive pulmonary disease, emphysema and diabetes   received a Moderna vaccine. Ten minutes later, she was having a hard time breathing. Soon she was unconscious. A nurse administered two EpiPens – one in a leg, and one in an arm, but they couldn’t save her.  She was gone in 15 minutes.  It had been a severe anaphylactic shock, despite the fact that she had never had an allergic reaction in the past.  Her daughter is  one of the first people in Canada to be compensated for a family member’s death under Canada’s Vaccine Injury Support Program.  The program started in June of 2021. So far it has 774 claims, eight claims have been already approved by the program’s medical review board. REFERENCES https://www.mapleridgenews.com/news/maple-ridge-woman-compensated-for-mothers-death-from-covid-19-vaccine/ https://canadatoday.news/bc/m...

  A 48-year-old woman complained of a tickle sensation in the throat and dyspnea 30 minutes after being administered the first dose of the Moderna coronavirus disease 2019 (COVID-19) vaccine. The patient had no history of hypertension, anxiety, or panic disorder. Forty-five minutes after the vaccination, stridor was noted, and the patient developed severe hypertension with a blood pressure of 197/153 mmHg. The patient also had tachycardia, cervical angioedema, and nausea, which occurred in a short period of time, indicating type I hypersensitivity reaction, that is, an anaphylactic reaction.  The patient had persistent nausea, conjunctival hyperemia, facial swelling, and nonpruritic angioedema in the neck.  The patient was diagnosed with Brighton classification Level 1 anaphylaxis caused by COVID-19 vaccination. For managing the patient, two intramuscular adrenaline injections, famotidine, chlorpheniramine, metoclopramide, and methylprednisolone were administered via int...